Patients with neovascular age-related macular degeneration in Spain display a high cardiovascular risk

European Journal of Ophthalmology

Volumn 22, Issue 3, 2012, Pages 404-411

  Olea, Jose Luis ^a   Tuñón, José ^b  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Age related macular degeneration; Cardiovascular; Risk factors

Indexed keywords

LIPID; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL CHOLESTEROL EDUCATION PROGRAM EXPERT PANEL CLINICAL GUIDELINES; OBSERVATIONAL STUDY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; RETINA MACULA AGE RELATED DEGENERATION; SPAIN;

AGED; ANGIOGENESIS INHIBITORS; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; MALE; PREVALENCE; RISK FACTORS; SPAIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84863308109     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000023     Document Type: Article

References (34)

1. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 2006; 6: 58.
2. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003; 290: 2057-2060.
3. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980; 24(suppl): 335-610.
4. VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000; 107: 1593-600.
5. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-389.
6. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419-421.
7. Yates JR, Sepp T, Matharu BK, et al, Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357: 553-561.
8. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology 1999; 106: 1056-1065.
9. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: a case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000; 107: 2224-2232.
10. Hyman L, Schachat AP, He Q, Leske MC, Age-Related Macular Degeneration Risk Factors Study Group. Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol 2000; 118: 351-358.
11. Doll R, Peto R. Mortality in relation to smoking: 20 yearsí observations on male British doctors. Br Med J 1976; 2: 1525-1536.
12. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study: II: Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol 1977; 106: 33-41.
13. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 1998; 116: 583-587.
14. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004; 111: 1280-1287.
15. Klein R, Klein B, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 2003; 110: 1273-1280.
16. Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Ophthalmology 2007; 114: 86-91.
17. Liew G, Mitchell P. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2007; 356: 747-748, author reply 749-750.
18. Tan JSL, Wang JJ, Liew G, Rochtchina E, Mitchell P. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 2008; 92: 509-512.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
20. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Circulation 2004; 110: 227-239.
21. Gabriel R, Alonso M, Segura A, et al, ERICE Cooperative Group. Prevalence, geographic distribution and geographic variability of major cardiovascular risk factors in Spain: pooled analysis of data from population-based epidemiological studies: the ERICE Study. Rev Esp Cardiol 2008; 61: 1030-1040.
22. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006; 92: 1752-1759.
23. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med 2005; 22: 554-562.
24. Donnan PT, Donnelly L, New JP, Morris AD. Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. Diabetes Care 2006; 29: 1231-1236.
25. Lee ET, Howard BV, Wang W, et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. Circulation 2006; 113: 2897-2905.
26. Turner ST, Schwartz GL, Boerwinkle E. Personalized medicine for high blood pressure. Hypertension 2007; 50: 1-5.
27. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
28. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280: C1358-C1366.
29. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002; 105: 373-379.
30. Tuñón J, Ruiz-Moreno JM, Martín-Ventura JL, Blanco-Colio LM, Lorenzo O, Egido J. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 2009; 54: 339-348.
31. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293: 1509-1513.
32. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726-733.
33. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009; 116: 362.
34. Gillies MC, Wong TY. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2007; 356: 748-749, author reply 749-50.